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Abstract  
 
Objective: Patient-reported outcomes (PROs) reflect treatment efficacy from the patients’ 
perspective. The objective was to assess PROs improvement with rituximab in rheumatoid 
arthritis. 
Methods: Patients with long-standing rheumatoid arthritis received rituximab 1000 mg twice 
at 2 weeks interval, and were assessed over 6 months. PROs including physical PROs (pain, 
functional assessment, physical quality of life) and mental or mixed aspects (fatigue, sleep 
and mental quality of life) were assessed. Standardized response means were calculated. 
Early improvement in PROs was used to predict EULAR response at 6 months. 
Results:  
For the 175 patients (mean age 54.6±10.6 years, mean disease duration 12.9±9.3 years), the 
plateau of efficacy of rituximab on PROs was reached at week 12, and the effect was more 
prominent on physical PROs (e.g., pain standardized response means -0.75 [95% 
confidence interval -0.91;-0.60]), than on sleep (-0.43; [-0.56;-0.29]). It was not possible to 
accurately predict 6-month EULAR response by early improvement in PROs. 
Conclusion: Rituximab was effective on PROs with an early effect. PROs reflecting physical 
aspects were more modulated by this biologic than other PROs (fatigue, sleep or mental 
quality of life). Links between sleep difficulties, fatigue and RA should be further studied. 
 
Keywords  
Rheumatoid arthritis, pain, sleep, quality of life, rituximab. 
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1. Introduction 
 
Patient-reported outcomes (PROs) reflect the patient’s perspective and are increasingly 
recognised as an important parameter in rheumatoid arthritis (RA) including when assessing 
treatment efficacy (1-5). PROs can be divided in outcomes related to physical aspects such 
as function or pain, and outcomes related to mental functioning e.g. depression but also 
probably fatigue or sleep.  
Trials of rituximab (RTX) have demonstrated its efficacy on RA disease activity, and on some 
essential PROs such as pain, functional impairment, fatigue and patient global assessment 
(PGA) (6-9). However, few data are available concerning the magnitude of effect of RTX on 
PROs or its impact on some aspects of the disease such as mental outcomes or sleep. 
Furthermore, because courses of RTX are usually administered at 6 month-intervals, 
patients may be anxious to know when (during this interval) they could experience 
improvement of their symptoms. Thus, it could be interesting to know the delay before onset 
of efficacy on PROs, as well as factors related to an early effect. 
Physicians would like to be able to predict response to therapy as early as possible. Our 
hypothesis is that patient’s assessment of efficacy, early on after a treatment change, could 
predict later efficacy on composite measures such as the disease activity score (DAS). If this 
is the case, it might allow earlier treatment changes, according to patients’ assessment. 
 
The objectives of the present study were to explore the effects of RTX on PROs, and in 
particular (a) to compare the improvement in PROs after RTX (b) to assess the delay before 
PROs improvement after the infusions and its predictive factors and (c) to assess if early 
patient-reported improvement was predictive of response, at week 24. 
 
2. Patients and Methods 
 
Study design 
SMART (eSsai MAbthera sur la dose de Re-Traitement) was a 2-year, national, multicenter, 
randomized, open-label study evaluating 2 strategies of re-treatment in patients responding 
to RTX after 1 course (1,000 mg on days 1 and 15)(11). In this ancillary study, only data from 
the first phase of the SMART trial were used: patients were treated with RTX (1000 mg twice, 
with a premedication of 100 mg of IV methylprednisolone each time) and followed-up 
(open-label phase), here only the first 6 months were analysed.  
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Patients 
Patients included had RA (according to American College of Rheumatology 1987 revised 
classification criteria (12)), and had active disease, defined by a Disease Activity Score in 28 
joints (DAS28) using the C-reactive protein (DAS28-CRP) of >3.2 associated with ≥6 of 66 
swollen joints and ≥6 of 68 tender joints, or a CRP level of ≥10 mg/liter (normal ≤5 mg/liter), 
or an erythrocyte sedimentation rate of ≥28 mm/hour. Each patient received a stable dose of 
methotrexate (≥10 mg/week for at least 4 weeks) and had experienced an inadequate 
response or intolerance to Tumor Necrosis Factor inhibitors. The population of interest 
included only patients with SF12 data at 6 months. 
Assessment of PROs and timeframe for improvement 
PROs assessed at baseline, week 6, 12 and 24 were pain and patient global assessment 
(PGA) by visual analogue scale (VAS), functional assessment by the Health Assessment 
Questionnaire, HAQ (13), fatigue (by VAS), and quality of sleep by the Medical Outcomes 
Study – MOS Sleep questionnaire (14). Quality of life (QoL) both mental and physical, was 
assessed by the Short-form 12 (SF12) at baseline and 24 weeks (15).  
Response to RTX at week 24 
Response at week 24 was defined according to changes in DAS levels by a EULAR good to 
moderate response (16). 
Statistical analyses 
Missing data were imputed using the last observation carried forward technique. 
To compare improvement in the different PROs after RTX treatment, standardised response 
means (SRMs) (change/ standard deviation, SD, of change) were calculated (17). 
Confidence intervals (95% CI) were estimated by bootstrapping. A SRM is usually 
considered large if > 0.8. To determine baseline predictive factors of early PGA 
improvement, PGA improvement of 30% at week 12 was explained by univariate logistic 
regression. Baseline explanatory variables included gender, age, disease duration, presence 
of radiological erosions, positivity of rheumatoid factor or anti cyclic citrullinated protein 
(CCP), DAS28 CRP, anaemia (haemoglobin <11 g/dl), oral glucocorticoid intake, HAQ and 
pain VAS. To assess if early response for PROs was associated with DAS response to RTX, 
both univariate logistic regression to explain EULAR good to moderate response (by DAS 28 
at week 24) and a 2x2 table were calculated.  
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3. Results  
 
Patient characteristics  
Of the 224 patients, 175 had SF12 data available at 6 months (Table 1): mean age was 54.6 
(± standard deviation 10.6) years, disease duration 12.9 (±9.3) years, and 146 (83.4%) were 
women. Patients reported high disease activity at baseline: mean DAS28-CRP 5.8 (±0.9). 
Rituximab was efficacious on disease activity: mean DAS28-CRP at 6 months was 4.2 
(±1.2). 
Patients had high symptom levels and in particular high pain and fatigue: mean baseline pain 
and fatigue VAS were respectively 60.7 (±21.6) mm and 62.6 (±22.3) mm. 
 
Effect of rituximab on different PROs 
PROs were improved after RTX (Table 2) but the effect at week 12 was much clearer on 
PGA, pain and HAQ than on sleep.  
A plateau for PROs was reached at week 12 with stability of results between 12 and 24 
weeks (figure 1). 
Neither demographic data, nor disease characteristics at baseline could predict an early 
improvement in PGA (data not shown). 
 
Prediction of DAS response by early PRO response 
PROs improvement seemed to be predictive for a moderate or good EULAR response at 
week 24, except fatigue at week 6 (supplementary online Table 1). 
However, the link between improvement in PROs at weeks 6 and 12 and the DAS28 
response at week 24 was low. Specifically, among patients presenting a DAS28 moderate or 
good response at week 24, 69 patients (66.3%%) had no improvement in PGA at week 6, 
and 45 (56.3%%) had no improvement in PGA at week 12. Reversely however, only 10 
patients at week 6 and 11 patients at week 12 with improved PGA had no DAS28 response 
at week 24. 
 
 
4. Discussion  
 
Assessment of PROs represents an important issue in studying efficacy of treatments in RA. 
In the present study, similarly to previous studies, RTX treatment led to improvement as 
measured by PROs (8, 9). Nevertheless, this study indicated that PROs reflecting physical 
aspects (pain, functional disability, PGA, physical quality of life) were more modulated by this 
biologic than other PROs (fatigue, sleep or mental quality of life). Specifically, this study is 
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the first to report the effects of RTX on sleep difficulties; small effect sizes indicate the link 
between sleep difficulties and the physiopathology of RA should be further studied. An 
interesting aspect is early prediction of response, through the patient’s assessment. In the 
present study, it was not possible to predict early on, either PRO response, nor DAS 
response using PROs. 
 
Our analysis has some limitations. Firstly, PROs are self-reported assessments and 
interpretation might be biased by treatment expectations, particularly at the early phases 
after treatment administration in such an open-label study. However, such expectations 
would modify all the outcomes, not only some of the PROs assessed here. Secondly, RA is a 
chronic disease, but PROs were studied here only over 24 weeks: it is possible impact on 
improvement in mental components could be observed later, after a sufficient delay, or after 
retreatments with RTX. 
 
The use of standardized response means allows the comparison of effects across different 
PROs; 0.80 represents a large response (18). Maximal effect on PROs was reached by week 
12 indicating that most patients will experience an improvement in their status by that time 
point. In the REFLEX study, Keystone et al found an improvement in PROs early on (at week 
4) in both the placebo and RTX groups, probably due to background steroids, and a 
significantly greater improvement was found only in the RTX group at week 8 (19). The 
present data brings more information on rapidity and sustainability of this efficacy on PROs. 
However, it was not possible to predict early improvement in PGA after 2 RTX infusions in 
the present study, which confirms the difficulties to predict response in RA patients (20). 
The effects of biologics on PROs is more and more studied, because it allows physicians to 
appreciate the effect of drugs according to the patient’s opinion. Other biologics have also 
demonstrated effects on PROs, which appear to be of a similar magnitude (21). 
 
Fatigue was improved after RTX in the present study, confirming previous results (9). 
However, ‘mental’ PROs including fatigue had less magnitude in response to RTX which 
brings new insights into the links between fatigue or quality of sleep and RA disease activity. 
 
Changes in PROs at week 6 and week 12 were associated with EULAR response to RTX at 
week 24, except fatigue at week 6. Thus, patients with no relevant improvement of fatigue at 
week 6 may still be responders at week 24: fatigue should not be a decision-making criterion 
in the early post-RTX therapy phase.  
Furthermore, the link between improvement in PGA and later improvement in DAS was low: 
a substantial number of patients who did not show relevant improvement in PGA at 6 or 12 
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weeks after the infusions still responded later to RTX in terms of DAS. Therefore it may be 
useful to continue with this treatment even when patients do not feel initial improvement.  
 
In conclusion, we demonstrated here the positive impact of RTX on physical PROs after the 
first course. “Mental” PROs (MOS sleep, mental quality of life) were not as significantly 
improved. These conclusions should be interpreted at an individual level, particularly in 
cases of multiple therapy failures. 
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Table 1.Baseline characteristics of 175 RA patients receiving a course of rituximab and 
followed up over 6 months 
 Total 
Females, n (%)  146 (83.4%) 
Age, years  54.6±10.6 
RA duration, years  12.9±9.3 
Presence of rheumatoid factor n (%)  114 (65.5%) 
Presence of anti-citrullinated protein antibodies n (%)  133 (76.4%) 
DAS28-CRP  5.8±0.9 
Pain VAS, mm  60.7±21.6 
Fatigue VAS, mm  62.6±22.3 
HAQ score 1.8±0.6  
Patient global VAS, mm  64.0±19.8 
MOS-Sleep 51.8±15.7 
SF12-physical 30.9±7.1 
SF12-mental 36.2±9.3 
Current prednisone use, n (%) 136 (77.7%) 
Methotrexate dosage, mg/week 14.1 (±3.6) 
Prednisone dosage for patients using it, mg/d 8.2 (±2.7) 
Except where indicated otherwise, values are the mean ± SD. DAS28-CRP = Disease 
Activity Score for 28 joints using the C-reactive protein level; HAQ = Health Assessment 
Questionnaire disability index; MOS-Sleep = Medical Outcomes Study Sleep questionnaire; 
SF-12: Short-Form 12 questionnaire, mental and physical components. 
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Table 2. Efficacy of rituximab on different PROs in 175 RA patients, ordered by decreasing 
response 
Outcome 
Improvement from baseline 
standardized response means [95%CI] 
Week 6 Week 12 Week 24 
DAS-28 CRP 
-1.11 
[-1.3 ; -0.93] 
-1.38 
[-1.57 ; -1.19] 
-1.3 
[-1.48 ; -1.11] 
Patient global (mm) 
-0.62 
[-0.77; -0.47] 
-0.83 
[-0.98; -0.68] 
-0.83 
[-0.98; -0.68] 
SF12-physical NA NA 
0.79 
[0.64; 0.93] 
Pain (mm) 
-0.53 
[-0.68 ; -0.37] 
-0.75 
[-0.91 ; -0.59] 
-0.75 
[-0.91 ; -0.6] 
Function (HAQ) 
-0.47 
[-0.61 ; -0.32] 
-0.68 
[-0.82 ; -0.54] 
-0.62 
[-0.75 ; -0.5] 
Fatigue (mm) 
-0.32 
[-0.47 ; -0.17] 
-0.55 
[-0.7 ; -0.41] 
-0.61 
[-0.76 ; -0.46] 
Sleep (MOS) 
-0.34 
[-0.48 ; -0.2] 
-0.44 
[-0.59 ; -0.3] 
-0.43 
[-0.56 ; -0.29] 
SF12-mental NA NA 
0.38 
[0.23; 0.53] 
NA : not available. 
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 Figure 1. Variation of different PROs in the 6 months following RTX.  
 
 
 
Week 6 
Week 12 Week 24 
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Online supplementary Table 1: Improvement in PROs at week 6 and week 12 and 
EULAR response at week 24 in univariate analysis 
Univariate analysis results 
 
No EULAR 
response at 
week 24 
N=49 
N (%) 
Moderate or good 
EULAR response at 
week 24 
N=125 
N(%) 
Odds ratio and P 
value (univariate 
analysis) 
Improvement in HAQ at 
week 6, yes versus no 
17 (21.5%) 
31 (35.2%) 
62 (78.5%) 
57 (64.8%) 
1.98 [0.99,3.96] 
0.053 
Improvement in VAS pain 
at week 6, yes versus no 
9 (15%) 
36 (33%) 
51 (85%) 
73 (67%) 
2.79 [1.24,6.30] 
0.01 
Improvement in VAS 
fatigue at  week 6, yes 
versus no 
10 (21.7%) 
35 (28.7%) 
36 (78.3%) 
87 (71.3%) 
1.45 [0.65,3.23] 
0.37 
Improvement in VAS PGA 
at week 6, yes versus no 
10 (15.4%) 
35 (33.7%) 
55 (84.6%) 
69 (66.3%) 
2.79 [1.27,6.13] 
0.01 
Reducing DAS 28 CRP at 
week 6, yes versus no 
15 (13.6%) 
30 (54.5%) 
95 (86.4%) 
25 (45.5%) 
7.60 [3.55,16.26] 
<0.0001 
Improvement in HAQ at 
week 12, yes versus no 
18 (18.8%) 
31 (41.3%) 
78 (81.3%) 
44 (58.7%) 
3.05 [1.53,6.08] 
0.002 
Improvement in VAS pain 
at week 12, yes versus no 
12 (12.9%) 
34 (43.6%) 
81 (87.1%) 
44 (56.4%) 
5.22 [2.46,11.08] 
<0.0001 
Improvement in VAS 
fatigue at week 12, yes 
versus no 
11 (16.9%) 
35 (33.3%) 
54 (83.1%) 
70 (66.7%) 
2.46 [1.14,5.27] 
0.02 
Improvement in VAS PGA 
at week 12, yes versus no 
11 (12.1%) 
35 (43.8%) 
80 (87.9%) 
45 (56.3%) 
5.66 [2.62,12.21] 
<0.0001 
Reducing DAS 28 CRP at 
week 12, yes versus no 
22 (16.4%) 
25 (71.4%) 
112 (83.6%) 
10 (28.6%) 
12.73 [5.36,30.20] 
<0.0001 
PGA : patient global assessment. VAS: visual analog scale. 
HAQ improvement was defined as a decrease of at least 0.22 points; VAS improvements 
were defined as a decrease of at least 30%. 
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Percentages are in line not columns 
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